Cargando…

Application of CRISPR-Cas9 gene editing technology in basic research, diagnosis and treatment of colon cancer

Colon cancer is the fourth leading cause of cancer death worldwide, and its progression is accompanied by a complex array of genetic variations. CRISPR/Cas9 can identify new drug-resistant or sensitive mutations in colon cancer, and can use gene editing technology to develop new therapeutic targets...

Descripción completa

Detalles Bibliográficos
Autores principales: Meng, Hui, Nan, Manman, Li, Yizhen, Ding, Yi, Yin, Yuhui, Zhang, Mingzhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067930/
https://www.ncbi.nlm.nih.gov/pubmed/37020597
http://dx.doi.org/10.3389/fendo.2023.1148412
_version_ 1785018580853587968
author Meng, Hui
Nan, Manman
Li, Yizhen
Ding, Yi
Yin, Yuhui
Zhang, Mingzhi
author_facet Meng, Hui
Nan, Manman
Li, Yizhen
Ding, Yi
Yin, Yuhui
Zhang, Mingzhi
author_sort Meng, Hui
collection PubMed
description Colon cancer is the fourth leading cause of cancer death worldwide, and its progression is accompanied by a complex array of genetic variations. CRISPR/Cas9 can identify new drug-resistant or sensitive mutations in colon cancer, and can use gene editing technology to develop new therapeutic targets and provide personalized treatments, thereby significantly improving the treatment of colon cancer patients. CRISPR/Cas9 systems are driving advances in biotechnology. RNA-directed Cas enzymes have accelerated the pace of basic research and led to clinical breakthroughs. This article reviews the rapid development of CRISPR/Cas in colon cancer, from gene editing to transcription regulation, gene knockout, genome-wide CRISPR tools, therapeutic targets, stem cell genomics, immunotherapy, metabolism-related genes and inflammatory bowel disease. In addition, the limitations and future development of CRISPR/Cas9 in colon cancer studies are reviewed. In conclusion, this article reviews the application of CRISPR-Cas9 gene editing technology in basic research, diagnosis and treatment of colon cancer.
format Online
Article
Text
id pubmed-10067930
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100679302023-04-04 Application of CRISPR-Cas9 gene editing technology in basic research, diagnosis and treatment of colon cancer Meng, Hui Nan, Manman Li, Yizhen Ding, Yi Yin, Yuhui Zhang, Mingzhi Front Endocrinol (Lausanne) Endocrinology Colon cancer is the fourth leading cause of cancer death worldwide, and its progression is accompanied by a complex array of genetic variations. CRISPR/Cas9 can identify new drug-resistant or sensitive mutations in colon cancer, and can use gene editing technology to develop new therapeutic targets and provide personalized treatments, thereby significantly improving the treatment of colon cancer patients. CRISPR/Cas9 systems are driving advances in biotechnology. RNA-directed Cas enzymes have accelerated the pace of basic research and led to clinical breakthroughs. This article reviews the rapid development of CRISPR/Cas in colon cancer, from gene editing to transcription regulation, gene knockout, genome-wide CRISPR tools, therapeutic targets, stem cell genomics, immunotherapy, metabolism-related genes and inflammatory bowel disease. In addition, the limitations and future development of CRISPR/Cas9 in colon cancer studies are reviewed. In conclusion, this article reviews the application of CRISPR-Cas9 gene editing technology in basic research, diagnosis and treatment of colon cancer. Frontiers Media S.A. 2023-03-20 /pmc/articles/PMC10067930/ /pubmed/37020597 http://dx.doi.org/10.3389/fendo.2023.1148412 Text en Copyright © 2023 Meng, Nan, Li, Ding, Yin and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Meng, Hui
Nan, Manman
Li, Yizhen
Ding, Yi
Yin, Yuhui
Zhang, Mingzhi
Application of CRISPR-Cas9 gene editing technology in basic research, diagnosis and treatment of colon cancer
title Application of CRISPR-Cas9 gene editing technology in basic research, diagnosis and treatment of colon cancer
title_full Application of CRISPR-Cas9 gene editing technology in basic research, diagnosis and treatment of colon cancer
title_fullStr Application of CRISPR-Cas9 gene editing technology in basic research, diagnosis and treatment of colon cancer
title_full_unstemmed Application of CRISPR-Cas9 gene editing technology in basic research, diagnosis and treatment of colon cancer
title_short Application of CRISPR-Cas9 gene editing technology in basic research, diagnosis and treatment of colon cancer
title_sort application of crispr-cas9 gene editing technology in basic research, diagnosis and treatment of colon cancer
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067930/
https://www.ncbi.nlm.nih.gov/pubmed/37020597
http://dx.doi.org/10.3389/fendo.2023.1148412
work_keys_str_mv AT menghui applicationofcrisprcas9geneeditingtechnologyinbasicresearchdiagnosisandtreatmentofcoloncancer
AT nanmanman applicationofcrisprcas9geneeditingtechnologyinbasicresearchdiagnosisandtreatmentofcoloncancer
AT liyizhen applicationofcrisprcas9geneeditingtechnologyinbasicresearchdiagnosisandtreatmentofcoloncancer
AT dingyi applicationofcrisprcas9geneeditingtechnologyinbasicresearchdiagnosisandtreatmentofcoloncancer
AT yinyuhui applicationofcrisprcas9geneeditingtechnologyinbasicresearchdiagnosisandtreatmentofcoloncancer
AT zhangmingzhi applicationofcrisprcas9geneeditingtechnologyinbasicresearchdiagnosisandtreatmentofcoloncancer